Table 1 Factors considered in offering re-irradiation as a treatment option
From: Expert consensus on re-irradiation for recurrent glioma
Responder number/(%) | ||||
|---|---|---|---|---|
Factor | Extremely relevant | Very relevant | Somewhat relevant | Not at all relevant |
Tumor volume | 5 (38) | 7 (54) | 1 (8) | 0 (0) |
Time since previous radiation therapy | 6 (46) | 6 (46) | 1 (8) | 0 (0) |
Dose previously administered to organs at risk in the field | 6 (46) | 4 (31) | 3 (23) | 0 (0) |
Patient performance status | 5 (38) | 4 (31) | 4 (31) | 0 (0) |
Patient age | 0 (0) | 8 (62) | 4 (31) | 1 (8) |
Original histology | 1 (8) | 4 (31) | 6 (46) | 2 (15) |
Number of lines of previous treatment | 0 (0) | 5 (38) | 6 (46) | 2 (15) |
Previous use of Bevacizumab or Bevacizumab failure | 1 (8) | 4 (31) | 6 (46) | 2 (15) |
Available tissue documentation of tumor progression | 1 (8) | 3 (23) | 7 (54) | 2 (15) |
Perfusion characteristics on diffusion weighted imaging (DWI) | 0 (0) | 6 (46) | 7 (54) | 0 (0) |
PET avidity of the lesion | 0 (0) | 4 (31) | 3 (23) | 6 (46) |